SCHEMBL1248078

SCHEMBL1248078

CCCNCCCCCCCNCCC

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.69
ALDH1A1 P00352 1/20 0.69
PAOX Q6QHF9 1/20 0.56
CYP2C19 P33261 2/20 0.56
CYP1A2 P05177 1/20 0.56
MEN1 O00255 1/20 0.50
GLA P06280 1/20 0.50
KMT2A Q03164 1/20 0.50
S1PR2 O95136 5/20 0.46
S1PR4 O95977 5/20 0.46
S1PR1 P21453 5/20 0.46
S1PR3 Q99500 5/20 0.46
S1PR5 Q9H228 1/20 0.46
EPHX1 P07099 2/20 0.46
ADH1B P00325 2/20 0.46
ADH1A P07327 2/20 0.46
ADH7 P40394 2/20 0.46
ADH1C P00326 1/20 0.46
ADH4 P08319 1/20 0.46
HRH4 Q9H3N8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11508516 1.00 TSHR (0.69) TSHRALDH1A1PAOXCYP2C19CYP1A2
SCHEMBL4211605 1.00 TSHR (0.69) TSHRALDH1A1PAOXCYP2C19CYP1A2
SCHEMBL1781797 1.00 TSHR (0.69) TSHRALDH1A1PAOXCYP2C19CYP1A2
SCHEMBL7512916 1.00 TSHR (0.69) TSHRALDH1A1PAOXCYP2C19CYP1A2
SCHEMBL11508173 1.00 TSHR (0.69) TSHRALDH1A1PAOXCYP2C19CYP1A2
SCHEMBL2639821 0.97 TSHR (0.65) TSHRALDH1A1PAOXCYP2C19CYP1A2
Bromide SCHEMBL7596439 0.97 TSHR (0.65) TSHRALDH1A1PAOXCYP2C19CYP1A2
Hydrochloric Acid SCHEMBL7512068 0.97 TSHR (0.65) TSHRALDH1A1PAOXCYP2C19CYP1A2
Hydrochloric Acid SCHEMBL7512398 0.97 TSHR (0.65) TSHRALDH1A1PAOXCYP2C19CYP1A2
Bromide SCHEMBL7601203 0.97 TSHR (0.65) TSHRALDH1A1PAOXCYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250017933-A1 CANCER TREATMENT USING LSD1 INHIBITORS AND PLK1 INHIBITORS CARDIFF ONCOLOGY, INC. 2025-01-16 US disclosed
US-20240018242-A1 METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY CHILDREN'S MEDICAL CENTER CORPORATION 2024-01-18 US disclosed
US-11685782-B2 Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy CHILDREN'S MEDICAL CENTER CORPORATION (US) 2023-06-27 US disclosed
WO-2023091932-A1 CANCER TREATMENT USING LSD1 INHIBITORS AND PLK1 INHIBITORS CARDIFF ONCOLOGY, INC. (US) 2023-05-25 WO disclosed
US-11382872-B2 LSD1 inhibitors as skeletal muscle hypertrophy inducers CYTOO (FR) 2022-07-12 US disclosed
WO-2013009372-A1 PHOSPHORUS-CONTAINING SECONDARY AMINE COMPOUNDS HUNTSMAN PETROCHEMICAL LLC (US) 2013-01-17 WO disclosed
EP-2467359-A2 (BIS) UREA AND (BIS) THIOUREA COMPOUNDS AS EPIGENIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS The Johns Hopkins University (US) 2012-06-27 EP disclosed
US-8080626-B2 Chain extenders ALBEMARLE CORPORATION (US) 2011-12-20 US disclosed
US-7964695-B2 Chain extenders ALBEMARLE CORPORATION (US) 2011-06-21 US disclosed
US-20110137005-A1 Chain Extenders ALBEMARLE CORPORATION (US) 2011-06-09 US disclosed
WO-2008039571-A1 DIAMINE CHAIN EXTENDER COMPOSITIONS ALBEMARLE CORPORATION (US) 2008-04-03 WO disclosed
US-20070270566-A1 Chain Extenders ALBEMARLE CORPORATION (US) 2007-11-22 US disclosed
US-4957640-A Corrosion prevention with compositions prepared from organic fatty amines and nitrogen-containing aromatic heterocyclic compounds THE DOW CHEMICAL COMPANY (US) 1990-09-18 US disclosed
US-4950411-A OIL AND GAS WELLS THE DOW CHEMICAL COMPANY (US) 1990-08-21 US disclosed
US-4871848-A OIL, GAS WELLS CORROSION INHIBITORS THE DOW CHEMICAL COMPANY (US) 1989-10-03 US disclosed
US-4765839-A PAVING THE DOW CHEMICAL COMPANY (US) 1988-08-23 US disclosed
US-4761473-A CORROSION RESISTANCE OF OIL OR GAS WELLS THE DOW CHEMICAL COMPANY (US) 1988-08-02 US disclosed
US-4740320-A REACTION OF NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPONENT, KETONE OR ALDEHYDE, AMINE OR POLYAMINE THE DOW CHEMICAL COMPANY (US) 1988-04-26 US disclosed
US-4724003-A Asphalt compositions containing anti-stripping additives prepared from hydrocarbyl substituted nitrogen-containing aromatic heterocyclic compounds, aldehydes or ketones and amines THE DOW CHEMICAL COMPANY (US) 1988-02-09 US disclosed
US-4009208-A N,N'-HEPTAMETHYLENEBIS(4-METHOXYBENZAMIDE) STERLING DRUG INC. (US) 1977-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250017933-A1 CANCER TREATMENT USING LSD1 INHIBITORS AND PLK1 INHIBITORS PLK1, KDM1B, EZH2 TSHR 4171/4885ALDH1A1 1850/4885PAOX 2685/4885
US-11685782-B2 Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy KDM1B, KDM2A, KDM3B TSHR 4077/4885ALDH1A1 876/4885PAOX 3102/4885
US-11382872-B2 LSD1 inhibitors as skeletal muscle hypertrophy inducers KDM1B, CPT1B, KDM1A TSHR 2720/4885ALDH1A1 1994/4885PAOX 2157/4885
US-20070270566-A1 Chain Extenders DDC, PARG, ODC1 TSHR 4124/4885ALDH1A1 146/4885PAOX 1145/4885
US-20240018242-A1 METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY KDM1B, KDM2A, KDM3B TSHR 4077/4885ALDH1A1 876/4885PAOX 3102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.